Spinomimetic Scaffold for Spinal Cord Injury Repair
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for spinal cord trauma and injury lack effective means to facilitate nerve regeneration due to challenges such as inflammation, scar tissue formation, and the need for multiple surgical interventions, while existing biomaterials have not provided sufficient biocompatibility and biodegradability to support neuronal repair.
Innovation Solution
A pharmaceutical composition comprising a crosslinked polyacrylonitrile (PANi), elastin (E), and collagen (C) polymer network that forms a spinomimetic scaffold with channels and tunnels, mimicking the spinal cord's structure to promote nerve growth and repair, utilizing covalent and non-covalent interactions to reorient protein secondary structures and provide elasticity and mechanical strength.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional biomaterials are used for spinal cord injury treatment, then surgical intervention can be performed, but the materials fail to provide sufficient biocompatibility and biodegradability to support neuronal repair
Solution Approach 1:
The patent employs a composite hydrogel system integrating multiple biomaterials (collagen, elastin, hyaluronic acid, and polyacrylonitrile) to achieve synergistic effects. This composite approach allows the scaffold to simultaneously provide structural support, biocompatibility, and controlled biodegradability, resolving the contradiction between material performance and ease of manufacture by creating a multifunctional material system rather than relying on single materials
Solution Approach 2:
The patent utilizes phase transition of gelatin at specific temperatures to control the gelation process. By changing temperature parameters, the system transitions from sol to gel state, enabling self-assembly and scaffold formation without complex manufacturing processes. This parameter-based control achieves high biocompatibility while maintaining manufacturing simplicity
2Reliability
If multiple surgical interventions are performed for spinal cord injury, then treatment can be attempted, but the number of interventions increases patient morbidity and treatment complexity
Solution Approach 1:
The pharmaceutical composition is designed to perform multiple functions simultaneously: it provides structural scaffolding for nerve regeneration, delivers anti-inflammatory medications, promotes axonal growth, and supports tissue engineering. This multi-functionality consolidates what would otherwise require multiple separate surgical interventions into a single comprehensive treatment approach, reducing patient morbidity while maintaining treatment effectiveness
Solution Approach 2:
The patent combines structural scaffold materials with pharmacologically active compounds into a single integrated implantable composition. This merging of structural and therapeutic functions allows the treatment to address multiple aspects of spinal cord injury (mechanical support, inflammation control, neuroregeneration) in one surgical procedure rather than requiring sequential interventions
3Reliability
If scar tissue formation occurs at the lesion site, then the body's natural response to injury is activated, but regrowth of axons is blocked and functional recovery is prevented
Solution Approach 1:
The patent incorporates anti-inflammatory medications within the scaffold to modulate the inflammatory response. By controlling and directing the inflammation process, the system converts the potentially harmful scar-forming response into a beneficial regulated healing process that supports axonal regeneration rather than blocking it. The inflammation is harnessed to clear debris and stimulate repair while preventing excessive scarring
4Reliability
If a pharmaceutical composition is designed to facilitate nerve repair, then chemical and physical cues are needed for neuronal regeneration, but the composition complexity increases
Solution Approach 1:
The patent employs a porous scaffold architecture that provides physical cues for neuronal growth through its structural features (pore size, interconnectivity, surface topology). This porous structure naturally guides axonal extension and cell migration without requiring additional complex chemical modifications. The physical architecture itself delivers the necessary regenerative cues, simplifying the overall composition design while maintaining high neuronal support capability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition minimizes inflammation, limits surgical interventions, preserves the blood-spinal barrier, reduces scar tissue formation, and supports neuronal growth and repair, demonstrating a spinomimetic scaffold that facilitates nerve regeneration and functional recovery in spinal cord injury models.
Implementation Method 1
utilizing covalent and non-covalent interactions to reorient protein secondary structures
Implementation Method 2
utilizing covalent and non-covalent interactions to reorient protein secondary structures
Implementation Method 3
provide elasticity and mechanical strength
Data Source
AI summary
A polyacrylonitrile (PANi) based pharmaceutical composition providing a porous implant for use in treating spinal cord trauma and/or spinal cord injury. Particularly a pharmaceutical composition including polyacrylonitrile (PANi) and/or elastin (E) and/or collagen (C) to form a PANi-E and/or PANi-C and/or a PANi-EC polymer network. Particularly, a pharmaceutical composition including polyacrylonitrile (PANi), elastin (E), and collagen (C) together forming a polyacrylonitrile (PANi), elastin (E), collagen (C) polymer network (PANi-E-C), wherein the polyacrylonitrile (PANi) may be crosslinked to form a crosslinked interpenetrating polyacrylonitrile (PANi), elastin (E) and collagen (C) polymer network (xpi-PANi-E-C), and wherein secondary protein structures of elastin (E) and collagen (C) reorientate. The disclosure extends to use of the pharmaceutical composition in the treatment of spinal cord trauma and/or spinal cord injury.